Ki67 targeted strategies for cancer therapy

被引：234

作者：

Yang, C. ^{[1
]}

Zhang, J. ^{[1
]}

Ding, M. ^{[1
,2
]}

Xu, K. ^{[1
,2
]}

Li, L. ^{[1
]}

Mao, L. ^{[1
,2
]}

Zheng, J. ^{[1
]}

机构：

[1] Xuzhou Med Univ, Jiangsu Key Lab Biol Canc Therapy, Xuzhou 221002, Peoples R China

[2] Univ Med Coll, Affiliated Hosp, Dept Urinary Surg, Xuzhou 221000, Peoples R China

来源：

CLINICAL & TRANSLATIONAL ONCOLOGY | 2018年 / 20卷 / 05期

关键词：

Ki67; Gene therapy; Renal cancer; siRNA; Target therapy; Proliferation; PROLIFERATION-ASSOCIATED ANTIGEN; SELECTIVE ADENOVIRUS ONYX-015; SMALL-INTERFERING-RNA; PHASE-I TRIAL; ONCOLYTIC ADENOVIRUS; ANTISENSE OLIGONUCLEOTIDE; PROSTATE-CANCER; BREAST-CANCER; INTRAVENOUS-INFUSION; ANTITUMOR-ACTIVITY;

D O I：

10.1007/s12094-017-1774-3

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Ki67 is a well-known proliferation marker for the evaluation of cell proliferation. Numerous studies have indicated that Ki67 index independently predicts cancer progression. Moreover, because Ki67 is highly expressed in malignant cells but almost could not be detected in normal cells, it has become a promising target for cancer therapy. In this review, we summarize recent advances in Ki67 targeted cancer therapy. In particular, we highlight recent development on the exploitation of Ki67 promoter to drive the expression of siRNAs or therapeutic genes in cancer cells specifically. The use of Ki67 as an attractive target opens a new avenue for cancer therapy.

引用

页码：570 / 575

页数：6

共 95 条

[1] Chemotherapy Induces Oral Mucositis in Mice Without Additional Noxious Stimuli [J].

Bertolini, M. ;

Sobue, T. ;

Thompson, A. ;

Dongari-Bagtzoglou, A. .

TRANSLATIONAL ONCOLOGY, 2017, 10 (04) :612-620

[2] The future of antisense therapy: combination with anticancer treatments [J].

Biroccio, A ;

Leonetti, C ;

Zupi, G .

ONCOGENE, 2003, 22 (42) :6579-6588

[3] An adenovirus mutant that replicates selectively in p53-deficient human tumor cells [J].

Bischoff, JR ;

Kim, DH ;

Williams, A ;

Heise, C ;

Horn, S ;

Muna, M ;

Ng, L ;

Nye, JA ;

SampsonJohannes, A ;

Fattaey, A ;

McCormick, F .

SCIENCE, 1996, 274 (5286) :373-376

[4] Correlation of amplification and overexpression of the c-myc oncogene in high-grade breast cancer:: FISH, in situ hybridisation and immunohistochemical analyses [J].

Blancato, J ;

Singh, B ;

Liu, A ;

Liao, DJ ;

Dickson, RB .

BRITISH JOURNAL OF CANCER, 2004, 90 (08) :1612-1619

[5] Oncolytic virotherapy for treatment of breast cancer, including triple-negative breast cancer [J].

Bramante, Simona ;

Koski, Anniina ;

Liikanen, Ilkka ;

Vassilev, Lotta ;

Oksanen, Minna ;

Siurala, Mikko ;

Heiskanen, Raita ;

Hakonen, Tiina ;

Joensuu, Timo ;

Kanerva, Anna ;

Pesonen, Sari ;

Hemminki, Akseli .

ONCOIMMUNOLOGY, 2016, 5 (02)

[6] Factor XI Antisense Oligonucleotide for Prevention of Venous Thrombosis [J].

Bueller, Harry R. ;

Bethune, Claudette ;

Bhanot, Sanjay ;

Gailani, David ;

Monia, Brett P. ;

Raskob, Gary E. ;

Segers, Annelise ;

Verhamme, Peter ;

Weitz, Jeffrey I. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (03) :232-240

[7] RNA-Based Therapeutics: Current Progress and Future Prospects [J].

Burnett, John C. ;

Rossi, John J. .

CHEMISTRY & BIOLOGY, 2012, 19 (01) :60-71

[8] IRF1 suppresses Ki-67 promoter activity through interfering with Sp1 activation [J].

Chen, Feifei ;

Song, Jian ;

Di, Jiehui ;

Zhang, Qing ;

Tian, Hui ;

Zheng, Junnian .

TUMOR BIOLOGY, 2012, 33 (06) :2217-2225

[9] Novel oncolytic adenovirus sensitizes renal cell carcinoma cells to radiotherapy via mitochondrial apoptotic cell death [J].

Chen, Ren-Fu ;

Li, Yue-Yan ;

Li, Lian-Tao ;

Cheng, Qian ;

Jiang, Guan ;

Zheng, Jun-Nian .

MOLECULAR MEDICINE REPORTS, 2015, 11 (03) :2141-2146

[10] Potential clinical applications of siRNA technique: benefits and limitations [J].

Chen, Shao-Hua ;

Zhaori, Getu .

EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2011, 41 (02) :221-232

← 1 2 3 4 5 6 7 8 9 10 →